bpc 157 news FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list FDA panel votes to ease

Right now the FDAs official explanation for thymosin alpha-1s place in the Category 2 list is that the safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug. Thymosin Alpha-1 Up for Review in 2027

The liver is able to convert a small amount of cyanocobalamin to methylcobalamin

In some cases, more advanced treatments such as immunosuppressants may be indicated, particularly for patients with autoimmune hepatitis

Thereby, the reported myotendinous junction recovery [43] and restoration of full function with the stable gastric pentadecapeptide BPC 157 therapy [43] might have particular therapy potential